



OPEN

Association between arterial stiffness and autonomic dysfunction in participants underwent treadmill exercise testing: a cross-sectional analysis

Sungjoon Park^{1,3}, Hack-Lyoung Kim^{1,3}, Kyung-Taek Park², Hyun Sung Joh¹, Woo-Hyun Lim¹, Jae-Bin Seo¹, Sang-Hyun Kim¹ & Myung-A Kim¹✉

Data on the impact of arterial stiffness on autonomic function are limited. We sought to investigate whether heart rate recovery (HRR), a predictor of autonomic function, is impaired in patients with increased arterial stiffness. A total of 475 participants (mean age 55.8 ± 11.1 years, 34.3% women) who underwent a treadmill exercise test (TET) for the evaluation of chest pain were retrospectively analyzed. All patients underwent brachial-ankle pulse wave velocity (baPWV) measurement on the same day. HRR was defined as the difference in heart rate from maximal exercise to 1 min of recovery. Participants with the lowest HRR tertile were older and had more cardiovascular risk factors than those with the highest HRR tertile. Simple correlation analysis showed that baPWV was negatively correlated with HRR ($r = -0.327$, $P < 0.001$). In multiple linear regression analysis, there was a significant association between baPWV and HRR, even after adjusting for potential confounders ($\beta = -0.181$, $P < 0.001$). In participants who underwent TET, baPWV was negatively correlated with HRR. The results of our study indicate a potential relationship between arterial stiffness and the autonomic nervous system.

Keywords arterial stiffness, autonomic function, heart rate recovery, pulse wave velocity, treadmill exercise test

Arterial stiffening is caused by the degradation of elastic fibers replaced by fibrosis, accumulation of lipids, migration of inflammatory cells, and proliferation of the smooth muscle cells of the arterial wall. This arterial remodeling process is accelerated by aging and other cardiovascular (CV) risk factors such as hypertension, diabetes, smoking, oxidative stress, and chronic inflammation^{1,2}. It is important to understand the concept of arterial stiffness because it is associated with the occurrence of mortality and CV events regardless of existing traditional risk factors^{3,4}. Consequently, information regarding arterial stiffness is primarily utilized in clinical settings to predict the subject's CV prognosis. Among several methods of measuring arterial stiffness, the pulse wave velocity (PWV) is the most widely used due to its non-invasiveness, simplicity, and reproducibility². Although carotid-femoral PWV (cfPWV) is considered the gold standard for arterial stiffness measurement among non-invasive methods⁵, the cfPWV measurement needs technical skill, and it may cause discomfort to the participants in finding carotid and femoral arteries⁶. On the other hand, brachial-ankle PWV (baPWV), developed later than cfPWV, is relatively simple to measure, takes less time, and has abundant clinical data^{4,6,7}. Thus, baPWV may be more advantageous for risk stratification in mass screenings. Recently, baPWV has been widely used to evaluate CV risk among many participants, especially in Asian countries⁸.

Resting heart rate (HR), a critical cardiac output parameter, is an important clinical sign in evaluating the hemodynamic status⁹. The autonomic nervous system and catecholamines influence HR in response to dynamic exercise¹⁰. The increase in HR during exercise is mainly increased by vagal withdrawal at the beginning of the

¹Division of Cardiology, Department of Internal Medicine, Boramae Medical Center, Seoul National University College of Medicine, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul 07061, Republic of Korea. ²Department of Cardiology, Chung-Ang University Hospital, Seoul, Republic of Korea. ³These authors contributed equally: Sungjoon Park and Hack-Lyoung Kim. ✉email: kma@snu.ac.kr

exercise. As HR reaches approximately 100 beats per minute or more, sympathetic activity further contributes to the rise. Following exercise termination, sympathetic nervous system activity rapidly decreases, and vagal tone is reactivated, leading to an exponential decrease in HR. Therefore, HR changes corresponding to different stages of exercise could serve as indicators of autonomic nervous system function^{11,12}. Autonomic dysfunction is closely related to CVD, especially arrhythmia, so HR changes during exercise stress tests may be applied to predict CVD^{13–15}. HR recovery (HRR) is defined as a difference between heart rate at peak exercise and within several minutes after resting during a treadmill exercise test (TET). HRR is known as a predictor of mortality independent from the treadmill exercise score^{15,16}.

Although arterial stiffness and HRR are important indicators for predicting CVD, there are only a few studies on the correlation between these two indicators^{17,18}. Knowing the relationship between these two variables is clinically significant because it can be applied to CV risk prediction or therapeutic development. Therefore, in this study, we aim to evaluate the association between baPWV and HRR in participants who underwent TET.

Methods

Study population

This single-center, retrospective study was conducted at the Boramae Medical Center in Seoul, Republic of Korea. The inclusion criteria for our study were adults aged 19 and older who presented with chest pain as their primary complaint during their initial visit to the center. These individuals underwent both TET and baPWV assessments on the same scheduled date, between January 2010 and November 2013. The measurement of baPWV was performed at the attending physician's discretion as part of the CV evaluation. Participants with the following clinical conditions were excluded: (1) unstable vital signs, (2) left ventricular (LV) ejection fraction < 50%, (3) valvular regurgitation or stenosis of more than mild degree, (4) presence of regional wall motion abnormality of LV, (5) pericardial effusion, (6) uncontrolled arrhythmia, and (7) ankle-brachial index < 0.9 or > 1.4.

This study was performed in line with the principles of the Declaration of Helsinki. The Institutional Review Board (IRB) of Boramae Medical Center (Seoul, Korea) approved the study protocol and waived written informed consent due to the retrospective study design and the routine nature of the information collected (IRB number, 16-2013-167).

Clinical data collection

Body mass index (BMI) was calculated as the ratio of the participants' weight in kilograms divided by the height in meters squared (kg/m^2). Using an oscillometric device, a trained nurse measured systolic BP (SBP) and diastolic BP (DBP). Hypertension was defined by a history of a hypertension diagnosis, SBP ≥ 140 mmHg, DBP ≥ 90 mmHg or current use of antihypertensive medications. Diabetes mellitus was defined by a history of the diagnosis of diabetes mellitus, fasting glucose level ≥ 126 mg/dL, glycated hemoglobin $\geq 6.5\%$ or current use of antidiabetic medications. Dyslipidemia was defined as a history of dyslipidemia diagnosis, low-density lipoprotein cholesterol ≥ 160 mg/dL or current use of antidiabetic medications. Patients who smoked regularly within the past 12 months were considered current smokers. A previous history of coronary artery disease and stroke was defined based on documented clinical diagnosis by a cardiologist and neurologist, respectively. The diagnosis of coronary artery disease was restricted to myocardial infarction and coronary revascularization, including percutaneous coronary intervention and bypass surgery. Data on concomitant antihypertensive medications, including renin-angiotensin system blockers, calcium channel blockers, beta-blockers, diuretics, and statins, were also obtained. Laboratory tests were performed after an overnight fasting of 12 h. Serum levels of hemoglobin, glycated hemoglobin, glucose, creatinine, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein, triglyceride, and high-sensitivity C-reactive protein were quantified. The estimated glomerular filtration rate (GFR) was calculated by the Modification of Diet in Renal Disease (MDRD) equation¹⁹. Transthoracic echocardiography was performed, and left ventricular ejection fraction was measured on the apical four- and two-chamber views using the biplane Simpson's method.

TET

A well-trained examiner conducted the TET using a commercially available device (GE healthcare CASE stress test system, Illinois, USA), following Bruce protocol²⁰: the initial speed of the treadmill was 1.7 mile/h with a slope of 10°; the second speed was 2.5 mile/h with a slope of 12°; the third speed was 3.4 mile/h with slope 14°; and the fourth speed was 4.2 mile/hour with slope 16°²¹. Surface 12-lead electrocardiogram (ECG) was continuously monitored, and brachial BP was measured at rest, at the end of each stress stage, peak stress, and recovery stage. The speed accelerated every 3 min. All HR and BP were measured in a sitting position. Termination of the procedure was based on the American Heart Association criteria: (1) a drop in SBP of 10 mmHg or more from the baseline in the absence of other evidence of ischemia, (2) ST-segment elevation (> 1.0 mm) in leads without Q waves (other than V1 or aVR), (3) severe anginal pain at a level that the participant will wish to stop exercising or more serious, (4) central nervous system symptoms (e.g., ataxia, dizziness, or near syncope), (5) signs of poor perfusion (cyanosis or pallor), (6) sustained ventricular tachycardia, (7) technical difficulties monitoring the ECG or SBP, (8) participants' request to stop²². Exercise capacity is the assessment of exercise performance quantified by metabolic equivalent tasks (METs). Exercise duration is defined as the total exercise time expressed as a second (s). ST segment change and positive final diagnosis are determined by the magnitude of exercise-induced ST displacement. ST segment change is specified as a horizontal or down-sloping ST deviation greater than 0.5 or 1.0 mm at 60 ms after the J point compared to the P-Q junction. Based on Duke score, which is an Arabic number composed of chest pain and ST depression, it is classified as high, intermediate, and low risk. These values correspond to low-risk (with a score of $\geq +5$), moderate-risk (with scores ranging from -10 to $+4$), and high-risk (with a score of ≤ -11). After exercise termination, participants rested in a sitting position, and

HR and BP were measured at 1 min and 2 min after the exercise. HRR was defined as the difference between the maximum HR during exercise and the HR 1 min after the test (HRR1). Although the difference between the maximum HR during exercise and the HR 2 min post-test (HRR2) displayed a correlation strength with baPWV comparable to HRR1 in univariable analysis (Supplementary Fig. S1), HRR1 exhibited a stronger correlation with baPWV in multivariable analysis (Supplementary Tables S1, S2). Based on the prior studies that identify BP response post-exercise as a crucial marker of autonomic function^{23,24}, we evaluated the changes in SBP and DBP at 2 and 3 min after the TET termination, comparing them to the peak BP levels observed during the TET.

baPWV measurement

The baPWV measurements were performed on the same day as TET. The volume-plethysmographic apparatus (VP-2000; Colin Co., Ltd., Komaki, Japan) was used to measure baPWV. Caffeine, alcohol consumption, and cigarette smoking were prohibited at least 12 h before the measurement. Patients were examined after resting in a quiet room in the supine position for a minimum of 5 min. Electrocardiographic electrodes were placed on both wrists, phonocardiographic electrodes were placed on the edge of the sternum to detect heart sounds, and pneumatic cuffs were wrapped around the upper arms and ankles. PWV value was calculated as a distance divided by transit time with the distance between measurement points estimated based on participant height²⁵. Transit time was derived from the start point of the brachial pulse wave to the start of the ankle pulse wave. The average value of left and right baPWV measurements was used for the study. A single well-trained staff member conducted the baPWV measurements. In our laboratory, the coefficient of variance for inter-observer reliability of baPWV was 5.1% in our laboratory²⁶.

Statistical analysis

Continuous variables are presented as the mean \pm standard deviation, while categorical variables are expressed as percentages. Participants were categorized into three groups based on HRR tertiles. The clinical characteristics of these groups were compared using analysis of variance for continuous variables and the Chi-square test for categorical variables. To explore univariable associations between two continuous variables, Pearson's bivariate correlation analysis was employed. Additionally, the study used multivariable linear regression analysis to investigate the independent association between baPWV and HRR. This analysis included all variables that showed statistical significance in the univariable analyses: sex, BMI, smoking status, high-density lipoprotein cholesterol, exercise capacity, SBP change at 3 min after exercise and resting and peak exercise HR. These potential confounders were controlled in the multivariable model using the forward selection method to ensure the robustness of the findings. To assess multicollinearity among explanatory variables, the variance inflation factor (VIF) was introduced. Multiple binary logistic regression analyses were conducted to evaluate whether a higher baPWV (≥ 1400 cm/s), indicative of abnormal arterial stiffening⁸ could predict lower HRR (< 26 beats/min, the median value). The same confounders were controlled for as those used in the multiple linear regression analysis. In the multivariable analyses, we evaluated model fit by comparing the changes in Akaike information criterion (AIC) and Bayesian information criterion (BIC) values that occurred upon adding baPWV as an independent variable. To visually represent and illustrate linear correlations between baPWV and HRR, scatter plots were utilized. Statistical significance was determined at a P value of less than 0.05. All statistical analyses were conducted using the SPSS 25.0 software (IBM Corp., Armonk, NY, USA).

Results

A total of 475 participants were analyzed. Two hundred and fifty-seven (54.1%) individuals completed the TET by achieving the target heart rate. The most common reason for early termination of TET was ST changes in 104 (21.9%) cases, followed by chest pain in 48 (10.1%) cases. The clinical characteristics of the study participants according to HRR tertile are presented in Table 1. The mean age was 55.8 ± 11.1 years, and 34.3% were female. Lower HRR was associated with more advanced age and a lower proportion of females compared to a higher HRR. Compared to participants with higher HRR, participants with lower HRR exhibited more CV risk factors, including a greater BMI, a higher BP, and the higher prevalence of hypertension, diabetes mellitus, cigarette smoking, and a previous history of coronary artery disease. CV medications, such as calcium channel blockers, beta-blockers, diuretics, and statins, were more frequently prescribed in participants with lower HRR than those with higher HRR. In laboratory findings, the blood levels of glucose, glycated hemoglobin, and creatinine were higher, and the blood levels of high-density lipoprotein cholesterol were lower in participants with lower HRR than those with higher HRR. Figure 1 demonstrates baPWV values according to HRR tertiles. baPWV gradually increased from the lowest to the highest tertile of HRR (baPWV: the lowest 1754 ± 207 cm/s, middle 1412 ± 61 cm/s, the highest 1202 ± 78 cm/s; $P < 0.001$). Table 2 shows TET results according to the HRR tertiles. Lower HRR was associated with decreased exercise capacity, duration, SBP at three minutes after exercise, and peak exercise HR. In Pearson's correlation analysis, baPWV negatively correlated with HRR ($r = -0.327$, $P < 0.001$). Figure 2 shows the linear relationship between baPWV and HRR. Table 3 shows the results of multiple linear regression analysis of factors associated with HRR. There was a significant association between baPWV and HRR even after adjusting for potential confounders ($\beta = -0.181$, $P < 0.001$). Multiple binary logistic regression model showed a similar finding that a higher baPWV ≥ 1400 cm/s was independently associated with a lower HRR (< 26 beats/min, the median value) (odds ratio, 1.92; 95% confidence interval 1.19–3.11; $P = 0.007$) (Table 4). The inclusion of baPWV in the multivariable analyses resulted in a reduction of both AIC and BIC values in both multiple linear regression (AIC, 2492 to 2480; BIC, 2531 to 2522) and logistic regression analyses (AIC, 452 to 447; BIC, 487 to 486). This indicates that models incorporating baPWV demonstrate a better fit. Female sex, BMI, current smoker, SBP change at 3 min after exercise, resting HR, and peak exercise HR were other significant risk factors associated with HRR in both multivariable models ($P < 0.05$ for each).

| Characteristic | HRR tertile | | | P |
|--------------------------------------|---------------------------------------|------------------------------------|---|---------|
| | The lowest (0–22 beats/min) (n = 161) | Middle (23–30 beats/min) (n = 156) | The highest (31–65 beats/min) (n = 158) | |
| Age (years) | 58.5 ± 11.1 | 56.1 ± 10.7 | 52.8 ± 10.7 | < 0.001 |
| Female sex | 40 (24.8) | 56 (35.8) | 67 (42.4) | 0.004 |
| Body mass index (kg/m ²) | 25.2 ± 3.3 | 24.8 ± 3.4 | 24.2 ± 2.8 | 0.020 |
| Systolic BP (mmHg) | 129.5 ± 14.7 | 126.2 ± 15.2 | 119.9 ± 15.5 | < 0.001 |
| Diastolic BP (mmHg) | 78.7 ± 9.0 | 76.2 ± 9.8 | 73.4 ± 10.6 | < 0.001 |
| Cardiovascular risk factors | | | | |
| Hypertension | 90 (55.9) | 70 (44.8) | 57 (36.0) | 0.002 |
| Diabetes mellitus | 38 (23.6) | 17 (10.9) | 17 (10.7) | 0.001 |
| Dyslipidemia | 61 (37.8) | 56 (35.8) | 32 (20.2) | 0.001 |
| Current smoker | 43 (26.7) | 29 (18.5) | 21 (13.2) | 0.010 |
| Coronary artery disease | 34 (21.1) | 31 (19.8) | 10 (6.3) | < 0.001 |
| Stroke | 3 (1.9) | 1 (0.6) | 0 | 0.180 |
| Cardiovascular medications | | | | |
| RAS inhibitors | 63 (39.1) | 48 (30.1) | 33 (20.9) | 0.002 |
| Calcium channel blockers | 70 (43.5) | 47 (29.7) | 23 (14.6) | < 0.001 |
| Beta-blockers | 51 (31.6) | 46 (29.4) | 16 (10.1) | < 0.001 |
| Diuretics | 18 (11.1) | 15 (9.6) | 3 (1.9) | 0.004 |
| Statin | 88 (54.7) | 77 (49.4) | 47 (29.7) | < 0.001 |
| Laboratory findings | | | | |
| Hemoglobin (g/dL) | 14.4 ± 2.1 | 14.2 ± 1.6 | 14.2 ± 1.4 | 0.717 |
| Glucose (mg/dL) | 115.6 ± 44.2 | 107.6 ± 27.7 | 99.5 ± 18.4 | < 0.001 |
| Glycated hemoglobin (%) | 6.2 ± 1.2 | 5.9 ± 0.9 | 5.7 ± 0.7 | 0.001 |
| Creatinine (mg/dL) | 0.96 ± 0.25 | 0.87 ± 0.18 | 0.85 ± 0.19 | < 0.001 |
| GFR (mL/min/1.73 m ²) | 81.2 ± 18.6 | 86.9 ± 17.0 | 90.4 ± 21.8 | < 0.001 |
| Total cholesterol (mg/dL) | 183.7 ± 40.0 | 187.0 ± 47.2 | 189.8 ± 35.6 | 0.426 |
| LDL cholesterol (mg/dL) | 113.9 ± 38.4 | 116.3 ± 38.4 | 118.4 ± 31.7 | 0.587 |
| HDL cholesterol (mg/dL) | 47.6 ± 11.3 | 48.5 ± 11.0 | 51.0 ± 11.5 | 0.031 |
| Triglyceride (mg/dL) | 130.4 ± 73.7 | 127.9 ± 79.9 | 113.8 ± 65.9 | 0.117 |
| C-reactive protein (mg/dL) | 0.26 ± 0.72 | 0.21 ± 0.58 | 0.15 ± 0.39 | 0.395 |
| LV ejection fraction (%) | 66.9 ± 5.9 | 67.4 ± 5.7 | 66.1 ± 7.4 | 0.301 |

Table 1. Clinical characteristics of study participants according to HRR tertile. Numbers are expressed as mean ± standard deviation or n (%). *HRR* heart rate recovery, *BP* blood pressure, *RAS* renin-angiotensin system, *GFR* glomerular filtration rate, *LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *LV* left ventricular.




Figure 1. baPWV values according to the HRR tertile. *baPWV* brachial-ankle pulse wave velocity, *HRR* heart rate recovery, *ANOVA* analysis of variance.

| Result variable | HRR tertile | | | P |
|---|---------------------------------------|------------------------------------|---|--------|
| | The lowest (0–22 beats/min) (n = 161) | Middle (23–30 beats/min) (n = 156) | The highest (31–65 beats/min) (n = 158) | |
| Exercise capacity, METs | 10.4 ± 2.6 | 10.9 ± 2.6 | 11.4 ± 1.8 | 0.010 |
| Exercise duration (s) | 526 ± 148 | 551 ± 113 | 586 ± 97 | <0.001 |
| Chest pain, yes | 22 (13.7) | 17 (10.9) | 9 (5.7) | 0.057 |
| ST segment change, yes | 38 (23.6) | 36 (23.1) | 30 (19.0) | 0.553 |
| Positive final diagnosis, yes | 40 (24.8) | 32 (20.5) | 23 (14.6) | 0.097 |
| Resting SBP (mmHg) | 129 ± 17 | 133 ± 18 | 124 ± 17 | <0.001 |
| Peak exercise SBP (mmHg) | 171 ± 26 | 176 ± 26 | 171 ± 25 | 0.157 |
| SBP change at 2 min after exercise (mmHg) | 12.1 ± 14.0 | 9.4 ± 13.9 | 7.7 ± 13.9 | 0.020 |
| SBP change at 3 min after exercise (mmHg) | 16.0 ± 16.4 | 19.7 ± 16.3 | 23.6 ± 17.0 | <0.001 |
| Resting DBP (mmHg) | 83.5 ± 12.0 | 85.1 ± 10.3 | 83.4 ± 12 | 0.416 |
| Peak exercise DBP (mmHg) | 70.0 ± 43.6 | 66.5 ± 48.2 | 63.2 ± 47.3 | 0.420 |
| DBP change at 2 min after exercise (mmHg) | 11.6 ± 11.7 | 12.2 ± 14.1 | 11.1 ± 15.5 | 0.804 |
| DBP at change 3 min after exercise (mmHg) | 12.0 ± 15.4 | 14.2 ± 18.0 | 13.8 ± 17.9 | 0.514 |
| Resting HR (beats/min) | 80.2 ± 13.4 | 77.4 ± 13.8 | 73.9 ± 12 | 0.001 |
| Peak exercise HR (beats/min) | 139.7 ± 21.8 | 147.3 ± 20.1 | 153.2 ± 16.0 | <0.001 |
| HRR (beats/min) | 16.0 ± 5.5 | 26.2 ± 2.4 | 36.9 ± 5.6 | <0.001 |

Table 2. The results of treadmill exercise test according to HRR tertile. Numbers are expressed as mean ± standard deviation or n (%). *HRR* heart rate recovery, *METs* metabolic equivalent tasks, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *HR* heart rate.




Figure 2. Linear correlation between baPWV and HRR. *baPWV* brachial-ankle pulse wave velocity, *HRR* heart rate recovery.

Discussion

This study demonstrated that increased baPWV was independently associated with attenuated HRR even after adjusting potential confounders in patients undergoing TET. In addition, other factors such as sex, obesity, smoking, recovery of SBP, resting HR, and peak exercise HR were related to attenuated HRR in multivariable analyses.

The regulation of the autonomic nerve system is crucial for maintaining the homeostasis of the CV system, particularly in controlling HR. During the intensive exercise, the parasympathetic nerve is withdrawn, and the sympathetic nerve is activated, leading to increased HR. After termination of exercise, HR exponentially decreases, primarily due to the predominance of the parasympathetic nerve over sympathetic withdrawal^{11,12}. HRR is a reliable and reproducible parameter that reflects immediate alterations in autonomic nerve function after the termination of exercise²⁷. Of note, it has been shown that slow HRR is associated with the severity of coronary artery disease in participants without traditional CV risk factors^{28,29}. Furthermore, it predicts future CV morbidity and mortality^{14,15}. Therefore, identifying clinical factors associated with HRR is meaningful for understanding the underlying pathophysiology and developing preventive or therapeutic strategies, especially among individuals at high coronary risk.

| Variable | β | P | VIF |
|--|---------|--------|-------|
| Female sex, yes | 0.153 | 0.001 | 1.244 |
| Body mass index (kg/m ²) | -0.166 | <0.001 | 1.087 |
| Current smoker, yes | -0.160 | <0.001 | 1.125 |
| High-density lipoprotein cholesterol (mg/dL) | 0.083 | 0.060 | 1.137 |
| Exercise capacity, METs | -0.145 | 0.006 | 1.599 |
| SBP change at 3 min after exercise (mmHg) | 0.181 | <0.001 | 1.026 |
| Resting HR (beats/min) | -0.447 | <0.001 | 1.590 |
| Peak exercise HR (beats/min) | 0.512 | <0.001 | 1.842 |
| baPWV (cm/s) | -0.181 | <0.001 | 1.174 |

Table 3. Multivariable linear regression analysis showing independent predictors for HRR. *HRR* heart rate recovery, *VIF* variance inflation factor, *METs* metabolic equivalent tasks, *SBP* systolic blood pressure, *HR* heart rate, *baPWV* brachial-ankle pulse wave velocity.

| Variable | OR (95% CI) | P |
|---|------------------|--------|
| Female sex, yes | 0.63 (0.37–1.05) | 0.080 |
| Body mass index ≥ 25 kg/m ² | 2.01 (1.25–3.22) | 0.004 |
| Current smoker, yes | 3.31 (1.75–6.23) | <0.001 |
| HDL cholesterol < 40 mg/dL | 1.99 (1.05–3.75) | 0.033 |
| Exercise capacity (METs), < median | 0.89 (0.54–1.47) | 0.663 |
| SBP change at 3 min after exercise (mmHg), < median | 0.50 (0.31–0.80) | 0.004 |
| Resting HR (beats/min), < median | 2.65 (1.55–4.53) | <0.001 |
| Peak exercise HR (beats/min), < median | 0.49 (0.29–0.83) | 0.009 |
| baPWV ≥ 1400 cm/s | 1.92 (1.19–3.11) | 0.007 |

Table 4. Multiple binary logistic regression analysis showing independent predictors for lower HRR (<26 beats/min, the median value). *HRR* heart rate recovery, *OR* odds ratio, *CI* confidence interval, *HDL* high-density lipoprotein, *METs* metabolic equivalent tasks, *SBP* systolic blood pressure, *HR* heart rate, *baPWV* brachial-ankle pulse wave velocity.

It has been suggested that HRR is associated with various CV risk factors, such as older age, smoking, chronic kidney disease, and metabolic syndrome^{30,31}. Several studies have reported a correlation between arterial stiffness and HRR^{17,18}. In a study of 209 healthy adults in the United States, aortic pulse wave velocity measured by magnetic resonance imaging was found to be significantly correlated with HRR¹⁸. Another Korean study of 154 normotensive patients without overt atherosclerosis demonstrated a significant association between baPWV and HRR¹⁷. In both studies, similar to ours, HRR was measured at 1 min after exercise. While these results were obtained from small studies, these findings are also in line with our findings, showing the association between arterial stiffness and HRR. Our data furnishes additional evidence regarding the pivotal role of arterial stiffness in the context of cardiac autonomic dysfunction.

Although the precise underlying pathophysiology of the association between arterial stiffness and HRR has yet to be elucidated, several hypotheses can be proposed. For instance, arterial stiffness might induce autonomic dysfunction through blunted baroreflex sensitivity^{32–34}. The baroreceptor is located in the carotid sinus and detects stretching of the aortic arch as BP increases. Arterial stiffening deforms the vascular wall components such as elastin, collagen, and vascular smooth muscle cells in baroreceptors of the aortic arch and carotid sinus. Arterial stiffening also causes carotid sinus hypertrophy and subsequently attenuates baroreceptor sensitivity, which detects fluctuation of intravascular pressure³⁵.

Clinical implications

For the proper clinical diagnosis and treatment of particular diseases, understanding the underlying pathophysiology is essential. While the function of the autonomic nervous system is crucial in the CV system, but the regulation of its function remains incompletely understood. Our study showed that HRR was associated with baPWV in participants who underwent TET, providing additional evidence on the possible role of arterial stiffness in regulating CV autonomic function. In addition, CV autonomic dysfunction may be suggested as another possible mechanism for the prognostic value of arterial stiffness in increasing the risk of CV events. Moreover, since baPWV is a noninvasive and simple measure, it can be used as a screening or monitoring tool for CV autonomic abnormality in high-risk individuals. Further studies are needed to determine whether methods that improve arterial stiffness can also improve HRR.

Study limitations

In addition to the retrospective design, there are several limitations of this study. First, our study did not confirm the causal relationship between baPWV and HRR, because of cross-sectional analysis. Moreover, demonstrating the association between baPWV and HRR does not necessarily imply a direct correlation between the results of baPWV and cardiac autonomic function. Second, we enrolled patients undergoing TET to evaluate chest discomfort; thus, we should be cautious when applying our results to other participant groups. Finally, while cfPWV is considered a golden standard non-invasive method for measuring arterial stiffness⁵, we conducted only baPWV measurements. However, it has been reported that baPWV correlated well with cfPWV³⁶ and invasive data²⁴. Additionally, the clinical values of baPWV have been shown in many clinical studies^{4,6,8}. Moreover, baPWV is more suitable as a screening tool because it is simpler and more convenient to measure than cfPWV⁶.

Conclusions

baPWV was negatively correlated with HRR in subjects who underwent TET. This result suggests a possible role of arterial stiffness in impaired cardiac autonomic response during exercise.

Data availability

All data generated or analyzed during this study are included in this published article.

Received: 18 June 2023; Accepted: 3 February 2024

Published online: 13 February 2024

References

- Lee, H. Y. & Oh, B. H. Aging and arterial stiffness. *Circ. J.* **74**, 2257–2262. <https://doi.org/10.1253/circj.cj-10-0910> (2010).
- Cavalcante, J. L., Lima, J. A., Redheuil, A. & Al-Mallah, M. H. Aortic stiffness: Current understanding and future directions. *J. Am. Coll. Cardiol.* **57**, 1511–1522. <https://doi.org/10.1016/j.jacc.2010.12.017> (2011).
- Vlachopoulos, C., Aznaouridis, K. & Stefanadis, C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: A systematic review and meta-analysis. *J. Am. Coll. Cardiol.* **55**, 1318–1327. <https://doi.org/10.1016/j.jacc.2009.10.061> (2010).
- Ohkuma, T. *et al.* Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: An individual participant data meta-analysis. *Hypertension* **69**, 1045–1052. <https://doi.org/10.1161/hypertensionaha.117.09097> (2017).
- Laurent, S. *et al.* Expert consensus document on arterial stiffness: Methodological issues and clinical applications. *Eur. Heart J.* **27**, 2588–2605. <https://doi.org/10.1093/eurheartj/ehl254> (2006).
- Kim, H. L. & Kim, S. H. Pulse wave velocity in atherosclerosis. *Front. Cardiovasc. Med.* **6**, 41. <https://doi.org/10.3389/fcvm.2019.00041> (2019).
- Yamashina, A. *et al.* Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. *Hypertens. Res.* **25**, 359–364. <https://doi.org/10.1291/hyres.25.359> (2002).
- Park, J. B. *et al.* Expert consensus on the clinical use of pulse wave velocity in Asia. *Pulse* **10**, 1–18. <https://doi.org/10.1159/000528208> (2022).
- Olshansky, B., Ricci, F. & Fedorowski, A. Importance of resting heart rate. *Trends Cardiovasc. Med.* <https://doi.org/10.1016/j.tcm.2022.05.006> (2022).
- Borresen, J. & Lambert, M. I. Autonomic control of heart rate during and after exercise: Measurements and implications for monitoring training status. *Sports Med.* **38**, 633–646. <https://doi.org/10.2165/00007256-200838080-00002> (2008).
- Pierpont, G. L., Adabag, S. & Yannopoulos, D. Pathophysiology of exercise heart rate recovery: A comprehensive analysis. *Ann. Noninvas. Electrocardiol.* **18**, 107–117. <https://doi.org/10.1111/anec.12061> (2013).
- Pierpont, G. L., Stolpman, D. R. & Gornick, C. C. Heart rate recovery post-exercise as an index of parasympathetic activity. *J. Auton. Nerv. Syst.* **80**, 169–174. [https://doi.org/10.1016/s0165-1838\(00\)00090-4](https://doi.org/10.1016/s0165-1838(00)00090-4) (2000).
- Jae, S. Y. *et al.* Relation of heart rate recovery after exercise testing to coronary artery calcification. *Ann. Med.* **49**, 404–410. <https://doi.org/10.1080/07853890.2017.1292044> (2017).
- Jouven, X. *et al.* Heart-rate profile during exercise as a predictor of sudden death. *N. Engl. J. Med.* **352**, 1951–1958. <https://doi.org/10.1056/NEJMoa043012> (2005).
- Qiu, S. *et al.* Heart rate recovery and risk of cardiovascular events and all-cause mortality: A meta-analysis of prospective cohort studies. *J. Am. Heart Assoc.* **6**, 5505. <https://doi.org/10.1161/jaha.117.005505> (2017).
- Kurl, S., Jae, S. Y., Vuolteenainen, A., Hagnäs, M. & Laukkanen, J. A. Exercise heart rate reserve and recovery as risk factors for sudden cardiac death. *Prog. Cardiovasc. Dis.* **68**, 7–11. <https://doi.org/10.1016/j.pcad.2021.09.002> (2021).
- Yang, I. H. *et al.* Slow heart rate recovery is associated with increased exercise-induced arterial stiffness in normotensive patients without overt atherosclerosis. *J. Cardiovasc. Imaging* **27**, 214–223. <https://doi.org/10.4250/jcvi.2019.27.e27> (2019).
- Fei, D. Y., Arena, R., Arrowood, J. A. & Kraft, K. A. Relationship between arterial stiffness and heart rate recovery in apparently healthy adults. *Vascular Health Risk Manag.* **1**, 85–89. <https://doi.org/10.2147/vhrm.1.1.85.58938> (2005).
- Levey, A. S. *et al.* A new equation to estimate glomerular filtration rate. *Ann. Intern. Med.* **150**, 604–612. <https://doi.org/10.7326/0003-4819-150-9-200905050-00006> (2009).
- Okin, P. M., Ameisen, O. & Kligfield, P. A modified treadmill exercise protocol for computer-assisted analysis of the ST segment/heart rate slope: Methods and reproducibility. *J. Electrocardiol.* **19**, 311–318. [https://doi.org/10.1016/s0022-0736\(86\)81058-5](https://doi.org/10.1016/s0022-0736(86)81058-5) (1986).
- Gibbons, R. J. *et al.* ACC/AHA 2002 guideline update for exercise testing: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). *Circulation* **106**, 1883–1892. <https://doi.org/10.1161/01.cir.0000034670.06526.15> (2002).
- Fletcher, G. F. *et al.* Exercise standards for testing and training: A statement for healthcare professionals from the American Heart Association. *Circulation* **104**, 1694–1740. <https://doi.org/10.1161/hc3901.095960> (2001).
- Laukkanen, J. A. *et al.* Elevated systolic blood pressure during recovery from exercise and the risk of sudden cardiac death. *J. Hypertens.* **32**, 659–666. <https://doi.org/10.1097/hjh.000000000000066> (2014).
- Kang, J. *et al.* Relationship between brachial-ankle pulse wave velocity and invasively measured aortic pulse pressure. *J. Clin. Hypertens. (Greenwich)* **20**, 462–468. <https://doi.org/10.1111/jch.13200> (2018).
- Sugawara, J., Hayashi, K. & Tanaka, H. Arterial path length estimation on brachial-ankle pulse wave velocity: Validity of height-based formulas. *J. Hypertens.* **32**, 881–889. <https://doi.org/10.1097/hjh.0000000000000114> (2014).
- Lee, H. S. *et al.* Incremental prognostic value of brachial-ankle pulse wave velocity to single-photon emission computed tomography in patients with suspected coronary artery disease. *J. Atheroscler. Thromb.* **22**, 1040–1050. <https://doi.org/10.5551/jat.29918> (2015).
- Manresa-Rocamora, A. *et al.* Exercise-based cardiac rehabilitation and parasympathetic function in patients with coronary artery disease: A systematic review and meta-analysis. *Clin. Auton. Res.* <https://doi.org/10.1007/s10286-020-00687-0> (2020).

28. Volkan Emren, S. *et al.* Decreased heart rate recovery may predict a high SYNTAX score in patients with stable coronary artery disease. *Bosnian J. Basic Med. Sci.* **19**, 109–115. <https://doi.org/10.17305/bjbm.2019.3725> (2019).
29. Carnethon, M. R. *et al.* Correlates of heart rate recovery over 20 years in a healthy population sample. *Med. Sci. Sports Exerc.* **44**, 273–279. <https://doi.org/10.1249/MSS.0b013e31822cb190> (2012).
30. Erat, M. *et al.* Evaluation of heart rate recovery index in heavy smokers. *Anat. J. Cardiol.* **16**, 667–672. <https://doi.org/10.5152/AnatolJCardiol.2015.6500> (2016).
31. Chang, R. Y. *et al.* Association between heart rate recovery after exercise and renal function in patients referred for treadmill exercise test. *PLoS ONE* **14**, e0222236. <https://doi.org/10.1371/journal.pone.0222236> (2019).
32. Tomiyama, H. *et al.* Pathophysiological contribution of vascular function to baroreflex regulation in hypertension. *Circ. J.* **78**, 1414–1419. <https://doi.org/10.1253/circj.cj-14-0064> (2014).
33. Chesterton, L. J., Sigrist, M. K., Bennett, T., Taal, M. W. & McIntyre, C. W. Reduced baroreflex sensitivity is associated with increased vascular calcification and arterial stiffness. *Nephrol. Dial. Transplant.* **20**, 1140–1147. <https://doi.org/10.1093/ndt/gfh808> (2005).
34. Lage, S. G., Polak, J. F., O'Leary, D. H. & Creager, M. A. Relationship of arterial compliance to baroreflex function in hypertensive patients. *Am. J. Physiol.* **265**, H232–H237. <https://doi.org/10.1152/ajpheart.1993.265.1.H232> (1993).
35. Tu, H., Zhang, D. & Li, Y. L. Cellular and molecular mechanisms underlying arterial baroreceptor remodeling in cardiovascular diseases and diabetes. *Neurosci. Bull.* **35**, 98–112. <https://doi.org/10.1007/s12264-018-0274-y> (2019).
36. Kollias, A., Kyriakoulis, K. G., Gravvani, A., Anagnostopoulos, I. & Stergiou, G. S. Automated pulse wave velocity assessment using a professional oscillometric office blood pressure monitor. *J. Clin. Hypertens. (Greenwich)* **22**, 1817–1823. <https://doi.org/10.1111/jch.13966> (2020).

Author contributions

S.P., H.-L.K. wrote the main manuscript text. K.-T.P., H.S.J., W.-H.L., J.-B.S., S.-H.K. prepared for investigation and editing. All authors fully reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-024-53681-1>.

Correspondence and requests for materials should be addressed to M.-A.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024